E. Mitry

发表

Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001

B Rachet, H Brenner, M. Coleman, 2004, British Journal of Cancer.

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases

M. Ychou, B. Nordlinger, R. Guimbaud, 2008, Cancer Chemotherapy and Pharmacology.

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

I. Pastan, J. Delgado, P. Zinzani, 2021, Journal of Hematology & Oncology.

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

C. Chabannon, M. Gilabert, E. Mitry, 2021, Cancers.

[Bleeding peptic ulcer: natural history and place of endoscopic hemostasis].

E. Mitry, P. Artru, G. Lesur, 2000, Gastroenterologie clinique et biologique.

Trends in gastric cancer incidence in a well-defined French population by time period and birth cohort

J. Faivre, C. Bonithon-Kopp, J. Estève, 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Revue De Presse

L. Siproudhis, Y. Panis, M. Bigard, 2007 .

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

P. Gestraud, O. Mariani, A. Vincent-Salomon, 2014, British Journal of Cancer.

Gastrinoma (Duodenal and Pancreatic)

R. Jensen, A. Scarpa, G. Klöppel, 2007, Neuroendocrinology.

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

A. Lièvre, P. Rougier, J. Bachet, 2009, International Journal of Colorectal Disease.

Assessment of patent foramen ovale in carcinoid heart disease.

P. Rougier, P. Lacombe, J. Farcot, 2006, American heart journal.

Valvular and Congenital Heart Disease Assessment of patent foramen ovale in carcinoid heart disease

P. Lacombe, J. Farcot, O. Dubourg, 2006 .

Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.

P. Rougier, O. Dubourg, N. Mansencal, 2008, The American journal of cardiology.

Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer

P. Rougier, E. Mitry, 2009, Alimentary pharmacology & therapeutics.

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

A. Lièvre, M. Ychou, P. Rougier, 2009, BMC Cancer.

Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases

B. Nordlinger, P. Rougier, C. Penna, 2005, The British journal of surgery.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases

B. Nordlinger, P. Rougier, B. Franc, 2006, Annals of surgery.

Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.

P. Rougier, O. Bouché, J. Seitz, 2005, Gastroenterologie clinique et biologique.

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

E. Van Cutsem, P. Rougier, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of the role of CPT-11 in the treatment of colorectal cancer.

P. Rougier, E. Mitry, 2001, Clinical colorectal cancer.

Chimiothérapie adjuvante du cancer du côlon

E. Mitry, 2006 .

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

R. Labianca, V. Torri, E. Van Cutsem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study

V. Jooste, J. Faivre, A. Bouvier, 2010, Gut.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

M. Loriot, P. Rougier, O. Bouché, 2015, Molecular Cancer Therapeutics.

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

J. Ezenfis, T. Aparicio, E. Mitry, 2004, British Journal of Cancer.

Elderly colorectal cancer patients are under treated

R. Labianca, A. Carrato, B. Daniele, 2004 .

Epidemiology, treatment and chemoprevention in colorectal cancer.

P. Rougier, E. Mitry, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly

J. Ezenfis, I. Etienney, T. Aparicio, 2003, British Journal of Cancer.

FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.

C. Cheze-le Rest, P. Laurent-Puig, H. Sokol, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The treatment of undifferentiated neuroendocrine tumors.

P. Rougier, E. Mitry, 2001, Critical reviews in oncology/hematology.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

M. Ychou, Y. Bécouarn, R. Guimbaud, 2011, Clinics and research in hepatology and gastroenterology.

A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.

E. Mitry, 2008, Cancer treatment reviews.

Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.

A. Lièvre, W. Cacheux, P. Michel, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Catherine Julié, Mostafa El Hajjam, Antoine Brouquet, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy in the treatment of anal canal carcinoma.

A. Lièvre, W. Cacheux, B. Buecher, 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centre.

A. Lièvre, B. Nordlinger, P. Rougier, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.

E. Baudin, C. Lombard-Bohas, P. Ruszniewski, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Tumeurs endocrines digestives

P. Rougier, E. Mitry, 2007 .

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE)

M. Ducreux, E. Baudin, V. Rohmer, 2017, Neuroendocrinology.

Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

P. Ravaud, P. Rougier, P. Ruszniewski, 2006, British Journal of Cancer.

Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials.

C. Tournigand, P. Rougier, D. Cunningham, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvement in colorectal cancer survival: a population-based study.

J. Faivre, J. Estève, A. Bouvier, 2005, European journal of cancer.

No evidence of somatic FGFR3 mutation in various types of carcinoma

J. Thiery, F. Radvanyi, E. Brambilla, 2001, Oncogene.

Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995.

J. Faivre, P. Hillon, F. Clinard, 1998, Journal of hepatology.

Malignant insulinoma: recommendations for characterisation and treatment.

A. Tabarin, E. Baudin, F. Pattou, 2013, Annales d'endocrinologie.

Pancreatic metastases: a multicentric study of 22 patients.

P. Rougier, A. Sauvanet, P. Lasser, 2004, Gastroenterologie clinique et biologique.

Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.

N. Pavlakis, S. Novello, S. Peters, 2019, Lung cancer.

Benefit of operative mortality reduction on colorectal cancer survival

J. Faivre, J. Estève, A. Bouvier, 2002, The British journal of surgery.

Survival from cancer of the colon in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from cancer of the rectum in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from cancer of the uterine cervix in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from cancer of the pancreas in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from cancer of the oesophagus in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from testicular cancer in England and Wales up to 2001

M. Coleman, B. Rachet, U. Nur, 2008, British Journal of Cancer.

Survival from cancer of the ovary in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Survival from cancer of the stomach in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Effectiveness of combined endoscopic ultrasound-guided fine-needle aspiration biopsy and stenting in patients with suspected pancreatic cancer

F. Prat, B. Terris, S. Chaussade, 2012, European journal of gastroenterology & hepatology.

Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors

P. Rougier, E. Mitry, 2000, Digestion.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials.

R. Labianca, V. Torri, E. Van Cutsem, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patent foramen ovale in carcinoid heart disease.

P. Rougier, O. Dubourg, N. Mansencal, 2010, International journal of cardiology.

Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease.

P. Rougier, W. McKenna, O. Dubourg, 2010, The American journal of cardiology.

Echocardiographic follow-up of treated patients with carcinoid syndrome.

P. Rougier, O. Dubourg, J. Bachet, 2010, The American journal of cardiology.

Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France

W. Cacheux, M. Ducreux, P. Rougier, 2008, Neuroendocrinology.

Erratum to: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

P. Rougier, A. Fohlen, J. Pelage, 2017, CardioVascular and Interventional Radiology.

Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

P. Rougier, A. Fohlen, J. Pelage, 2016, CardioVascular and Interventional Radiology.

[Treatment strategy for pancreatic endocrine tumours].

P. Rougier, E. Mitry, 2003, Gastroenterologie clinique et biologique.

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

M. Ducreux, E. Baudin, P. Rougier, 2014, European journal of cancer.

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

P. Rougier, J. Raoul, J. Seitz, 2009, Endocrine-related cancer.

Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?

B. Nordlinger, M. Housset, P. Rougier, 2007, Gastroenterologie clinique et biologique.

Traitement adjuvant du cancer du pancréas

P. Rougier, E. Mitry, C. Lepère, 2005, Oncologie.

Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577)

M. Ducreux, P. Rougier, J. Breau, 2004 .

Unmet needs and challenges in gastric cancer: the way forward.

Fátima Carneiro, Josep Tabernero, William Allum, 2014, Cancer treatment reviews.

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.

M. Loriot, P. Laurent-Puig, C. Lepage, 2013 .

[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].

M. Ducreux, P. Rougier, F. Eschwège, 1999, Bulletin du cancer.

289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

P. Rougier, J. Raoul, M. Peeters, 2003 .

1091 How to explain the improvement in survival for colorectal cancer? A French population-based study

J. Estève, A. Bouvier, E. Mitry, 2003 .

Risk of venous thrombosis in patients with pancreatic adenocarcinoma.

A. Lièvre, P. Rougier, O. Dubourg, 2007, Gastroentérologie Clinique et Biologique.

MICI et cancer colorectal. Surveillance

E. Mitry, G. Lesur, 1999, Acta Endoscopica.

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

M. Ychou, P. Rougier, T. Mazard, 2014, Gastric Cancer.

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

I. Sobhani, P. Laurent-Puig, F. Bonnetain, 2013, British Journal of Cancer.

Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab

A. Lièvre, P. Rougier, A. Lacout, 2008, Journal of Neurology.

Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study

F. Caillol, Jean-Philippe Ratone, M. Giovannini, 2022, Frontiers in Oncology.

Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).

M. Ducreux, E. Baudin, P. Ruszniewski, 2012 .

Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study).

M. Ducreux, J. Seitz, D. O'Toole, 2012 .

Avdoralimab (anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FORCE)

F. Meziani, F. Rotolo, L. Velly, 2022, SSRN Electronic Journal.

255 Oxaliplatin or irinotecan based chemotherapy for metastic colorectal cancer in the elderly

I. Etienney, T. Aparicio, E. Mitry, 2003 .

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

B. Chauffert, M. Ychou, P. Rougier, 2010, Gut.

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

M. Ychou, E. Assenat, J. Biagi, 2022, JAMA oncology.

Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017, The New England journal of medicine.

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

Emmanuel Mitry, E. Mitry, 1990, The New England journal of medicine.

Hepatocellular carcinoma (HCC): an update.

P. Rougier, J. Taieb, E. Mitry, 2007, Seminars in oncology.

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

M. Ducreux, E. Baudin, M. Schlumberger, 1999, British Journal of Cancer.

Survival from cancer of the breast in women in England and Wales up to 2001

B Rachet, M. Coleman, B. Rachet, 2008, British Journal of Cancer.

Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.

V. Vilgrain, M. Ducreux, E. Baudin, 2014, European journal of cancer.

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

I. Sobhani, J. Taïeb, F. Bonnetain, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Renal Cell Carcinoma with Gastric Metastases

M. Gutiérrez, H. Errihani, E. Mitry, 2012, Journal of Gastrointestinal Cancer.

Role of microsatellite instability in the management of colorectal cancers.

A. Lièvre, W. Cacheux, B. Buecher, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach Versus Molecular Screening

F. Radvanyi, P. Laurent-Puig, B. Nordlinger, 2008, The American Journal of Gastroenterology.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab efficacy in patients treated routinely in university hospitals.

A. Lièvre, F. Lévi, P. Rougier, 2007, Gastroenterologie clinique et biologique.

Safety and efficacy of palliative systemic chemotherapy combined with colorectal self-expandable metallic stents in advanced colorectal cancer: A multicenter study.

B. Landi, D. Moussata, A. Charachon, 2016, Clinics and research in hepatology and gastroenterology.

[Colorectal cancer management].

P. Rougier, E. Mitry, M. Clavero-Fabri, 2004, La Revue du praticien.

Surgery for colon and rectal cancer.

B. Nordlinger, C. Penna, E. Mitry, 2002, Best practice & research. Clinical gastroenterology.

Unbalance between plasma levels of Protein Z and protein Z-dependent inhibitor in patients with colorectal and pancreatic cancer: a pilot study.

J. Botton, S. Doat, E. Bianchini, 2014, Thrombosis research.

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.

M. Ychou, P. Rougier, F. Bonnetain, 2010, European journal of cancer.

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

M. Ducreux, P. Rougier, J. Breau, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Colorectal adenocarcinoma in patients under 45 years of age: Comparison with older patients in a well-defined french population

J. Faivre, J. Jouve, F. Clinard, 2001, Diseases of the colon and rectum.

Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study.

M. Coleman, G. Gatta, K. Pritchard-Jones, 2006, European journal of cancer.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma

O. Mariani, S. Vacher, S. Richon, 2017, Oncotarget.

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.

J. Scoazec, R. Guimbaud, C. Dromain, 2013, Endocrine-related cancer.

Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC.

L. Zhang, Se-Hoon Lee, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis

F. Bonnetain, J. Jouve, M. Gasmi, 2008 .

Pulmonary resection for metastases of colorectal adenocarcinoma.

A. Cazes, C. Foucault, A. Dujon, 2010, The Annals of thoracic surgery.

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

E. Raymond, P. Hérait, G. Deplanque, 2012 .

Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients

I. Sobhani, F. Roudot-thoraval, C. Hennequin, 2009, Alimentary pharmacology & therapeutics.

[Chemotherapy with curative intent before (neoadjuvant) or after (adjuvant) surgery for colorectal cancer liver metastases].

P. Rougier, R. Guimbaud, E. Mitry, 2003, Bulletin de l'Academie nationale de medecine.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer

E. Raymond, J. Kinet, P. Rougier, 2010, Cancer Chemotherapy and Pharmacology.

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

I. Sobhani, O. Boulat, O. Bouché, 2017, European journal of cancer.

Cancer survival in England and Wales at the end of the 20th century

M. Coleman, H. Brenner, B. Rachet, 2008, British Journal of Cancer.

Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma.

M. Ducreux, P. Rougier, J. Taïeb, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

O. Bouché, M. Ramdani, J. Seitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival from cancer of the uterus in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences

O. Mariani, S. Vacher, S. Richon, 2018, Cancer medicine.

Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.

A. Shaw, T. Mok, P. N. Morcos, 2018 .

Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC).

Se-Hoon Lee, C. Zhou, Y. Cheng, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC

N. Pavlakis, A. Shaw, T. Mok, 2018, Pneumologie.

Chemotherapy in elderly patients with colorectal cancer.

R. Goldberg, C. Köhne, G. Folprecht, 2008, The oncologist.

Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.

A. Lièvre, P. Rougier, B. Landi, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.

M. Ducreux, P. Rougier, J. Taïeb, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[Malignant insulinoma: recommendations for workup and treatment].

A. Tabarin, E. Baudin, F. Pattou, 2014, Presse medicale.

Survival from Uveal Melanoma in England and Wales 1986 to 2001

M. Coleman, B. Rachet, E. Mitry, 2007, Ophthalmic epidemiology.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

D. Sargent, E. Van Cutsem, M. Aapro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

D. Aust, T. Conroy, J. Neoptolemos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors

M. Pavel, B. Annibale, M. Platania, 2009, Neuroendocrinology.

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection

S. Richon, A. Lièvre, W. Cacheux, 2016, British Journal of Cancer.

Epidemiology and survival in patients with carcinoid disease in the Netherlands — An epidemiological study with 2391 patients, P.F. Quaedvlieg, O. Visser, C. Lamers, M.L. Janssen-Heijen, B. Taal, in: Ann Oncol, 12. (2001), 1295

E. Mitry, 2006 .

Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome

F. Radvanyi, P. Laurent-Puig, B. Nordlinger, 2012, International journal of cancer.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

R. Stephens, E. Van Cutsem, L. Saltz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of the elderly colorectal cancer patient: SIOG expert recommendations.

J. Horiot, E. Van Cutsem, M. Aapro, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study

M. Ducreux, E. Baudin, C. Lombard-Bohas, 2011, The International journal of biological markers.

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

Survival from bladder cancer in England and Wales up to 2001

B Rachet, M. Coleman, B. Rachet, 2008, British Journal of Cancer.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Evidence of improving survival of patients with rectal cancer in France: a population based study

G. Launoy, J. Faivre, J. Maurel, 1999, Gut.

Survival from uveal melanoma in England and Wales: 1986-1999

M. Coleman, E. Mitry, J. Burr, 2004 .

Autoimmune pancreatitis with atypical imaging findings that mimicked an endocrine tumor.

P. Rougier, P. Hammel, L. Palazzo, 2010, World journal of gastroenterology.

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.

F. Bonnetain, O. Hentic, B. Landi, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Rationnel du dépistage

E. Mitry, 2006 .

Assessment of biological effect of nab-paclitaxel combined with gemcitabine, using contrast enhanced ultrasonography and elastography, in advanced pancreatic ductal carcinoma: A single-center pilot study

M. Giovannini, C. Zemmour, E. Mitry, 2023, Endoscopic ultrasound.

The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments.

N. Salem, F. Poizat, M. Giovaninni, 2023, Brachytherapy.

Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study.

A. Thiébaut, P. Ricordeau, S. Doat, 2014, European journal of cancer.

Survival from multiple myeloma in England and Wales up to 2001

M. Coleman, B. Rachet, A. Shah, 2008, British Journal of Cancer.

Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study.

A. Shaw, T. Mok, S. Peters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy for colon cancer in a well‐defined French population: is it under‐ or over‐prescribed?

C. Faivre-Finn, J. Faivre, A. Bouvier, 2002, Alimentary pharmacology & therapeutics.

Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study.

E. Raymond, P. Rougier, G. Deplanque, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients.

A. Lièvre, P. Rougier, J. Emile, 2009, Gastroentérologie Clinique et Biologique.

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Adjuvant chemotherapy for colon adenocarcinoma in the county of Côte-d'Or].

J. Faivre, J. Jouve, M. A. Tazi, 1998, Gastroentérologie Clinique et Biologique.

Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases

F. Penault-Llorca, P. Rougier, H. Blons, 2012, European journal of gastroenterology & hepatology.

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

N. Girard, R. Boidot, J. Iovanna, 2022, BMC cancer.

410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study

S. Ou, T. Mok, S. Peters, 2017 .

Survival from adult leukaemia in England and Wales up to 2001

M. Coleman, B. Rachet, A. Shah, 2008, British Journal of Cancer.

[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].

M. Ducreux, P. Rougier, J. Taïeb, 2002, Gastroenterologie clinique et biologique.

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2017 .

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

M. Ducreux, P. Rougier, J. Breau, 2006, Gastroenterologie clinique et biologique.

Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

M. Vetizou, B. Coutard, F. Carrette, 2020, Nature.

Primary Colectomy in Patients With Stage IV Colon Cancer and Unresectable Distant Metastases Improves Overall Survival: Results of a Multicentric Study

I. Sobhani, F. Roudot-thoraval, B. Landi, 2011, Diseases of the colon and rectum.

Malignant insulinoma: recommendations for characterisation and treatment.

A. Tabarin, E. Baudin, F. Pattou, 2013, Annales d'endocrinologie.

Survival from non-Hodgkin lymphoma in England and Wales up to 2001

M. Coleman, B. Rachet, A. Shah, 2008, British Journal of Cancer.

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.

T. de Baère, T. Baère, E. Baudin, 2001, European journal of cancer.

[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].

T. Conroy, E. Mitry, 2011, Bulletin du cancer.

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?

C. Lepage, V. Jooste, J. Faivre, 2013, European journal of cancer.

Current treatment options for advanced colorectal cancer.

P. Rougier, E. Mitry, 2000, Seminars in oncology.

1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial

T. Conroy, J. Iovanna, J. Biagi, 2022, Annals of Oncology.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

E. Van Cutsem, P. Rougier, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Malignant insulinoma: recommendations for characterisation and treatment.

A. Tabarin, E. Baudin, F. Pattou, 2013, Annales d'endocrinologie.

Chemotherapy and medical treatment of hepatocellular carcinoma (HCC).

P. Rougier, E. Mitry, M. Clavero-Fabri, 1998, Hepato-gastroenterology.

Unmet needs and challenges in gastric cancer: the way forward.

E. Van Cutsem, F. Lordick, J. Tabernero, 2014, Cancer treatment reviews.

Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan.

E. Van Cutsem, L. Saltz, C. Köhne, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete radiological response of colorectal liver metastases (LM) after chemotherapy: Does it mean cure?

B. Nordlinger, P. Rougier, S. Chagnon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer

V. Boige, O. Bouché, L. Mineur, 2023, JAMA network open.

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301)

M. Ychou, C. Mariette, J. Raoul, 2008 .

Survival from brain tumours in England and Wales up to 2001

M. Coleman, B. Rachet, M. Quinn, 2008, British Journal of Cancer.

Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: Results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study.

E. Raymond, G. Deplanque, F. Goldwasser, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976–1995

C. Faivre-Finn, J. Faivre, F. Clinard, 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.